Corrigendum to "Alzheimer disease: Amyloidogenesis, the presenilins and animal models" [Biochim. Biophys. Acta 1772 (2007) 285-297] (DOI:10.1016/j.bbadis.2006.12.001);Alzheimer disease: Amyloidogenesis, the presenilins and animal models

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1772, Issue 3, 2007, Pages 285-297

  Newman, M ^a   Musgrave, F I ^a   Lardelli, M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Alzheimer's disease; Amyloid beta; Animal models; Oxidative stress; Presenilin; Zebrafish

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; COMPLEMENTARY DNA; GAMMA SECRETASE; PRESENILIN 1; T LYMPHOCYTE RECEPTOR;

ALZHEIMER DISEASE; AMYLOIDOGENESIS; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; DISEASE MODEL; FAMILIAL DISEASE; GENE; GENE EXPRESSION REGULATION; INFLAMMATION; MOLECULAR MECHANICS; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; PS1 GENE; PS2 GENE; REVIEW; ZEBRA FISH;

ANIMALIA; DANIO RERIO;

EID: 33847049400     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.12.010     Document Type: Erratum

References (144)

1. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
2. Pratico D., and Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. 109 (2000) 577-585
3. Selkoe D.J., and Podlisny M.B. Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet. 3 (2002) 67-99
4. Artero S., Tierney M.C., Touchon J., and Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr. Scand. 107 (2003) 390-393
5. Lambon Ralph M.A., Patterson K., Graham N., Dawson K., and Hodges J.R. Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases. Brain 126 (2003) 2350-2362
6. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
7. Taguchi K., Yamagata H.D., Zhong W., Kamino K., Akatsu H., Hata R., Yamamoto T., Kosaka K., Takeda M., Kondo I., and Miki T. Identification of hippocampus-related candidate genes for Alzheimer's disease. Ann. Neurol. 57 (2005) 585-588
8. Cotman C.W., and Su J.H. Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol. 6 (1996) 493-506
9. Aslan M., and Ozben T. Reactive oxygen and nitrogen species in Alzheimer's disease. Curr. Alzheimers Res. 1 (2004) 111-119
10. Butterfield D.A., Griffin S., Munch G., and Pasinetti G.M. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J. Alzheimers Dis. 4 (2002) 193-201
11. Opazo C., Huang X., Cherny R.A., Moir R.D., Roher A.E., White A.R., Cappai R., Masters C.L., Tanzi R.E., Inestrosa N.C., and Bush A.I. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277 (2002) 40302-40308
12. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., Scarpa R.C., Saunders A.J., Lim J., Moir R.D., Glabe C., Bowden E.F., Masters C.L., Fairlie D.P., Tanzi R.E., and Bush A.I. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274 (1999) 37111-37116
13. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E., and Bush A.I. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38 (1999) 7609-7616
14. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S., and Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304 (2004) 448-452
15. Sastre M., Klockgether T., and Heneka M.T. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci. 24 (2006) 167-176
16. Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., Silverstein S.C., and Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9 (2003) 453-457
17. Tuppo E.E., and Arias H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37 (2005) 289-305
18. Weldon D.T., Rogers S.D., Ghilardi J.R., Finke M.P., Cleary J.P., O'Hare E., Esler W.P., Maggio J.E., and Mantyh P.W. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci. 18 (1998) 2161-2173
19. Guillemin G.J., Williams K.R., Smith D.G., Smythe G.A., Croitoru-Lamoury J., and Brew B.J. Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv. Exp. Med. Biol. 527 (2003) 167-176
20. Kitaguchi N., Takahashi Y., Tokushima Y., Shiojiri S., and Ito H. Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. Nature 331 (1988) 530-532
21. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., and Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1 (1992) 345-347
22. De Strooper B., Umans L., Van Leuven F., and Van Den Berghe H. Study of the synthesis and secretion of normal and artificial mutants of murine amyloid precursor protein (APP): cleavage of APP occurs in a late compartment of the default secretion pathway. J. Cell Biol. 121 (1993) 295-304
23. Kirkitadze M.D., and Kowalska A. Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. Acta Biochim. Pol. 52 (2005) 417-423
24. Cuajungco M.P., and Faget K.Y. Zinc takes the center stage: its paradoxical role in Alzheimer's disease. Brain Res. Brain Res. Rev. 41 (2003) 44-56
25. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
26. Bird T.D. Genetic factors in Alzheimer's disease. N. Engl. J. Med. 352 (2005) 862-864
27. Capell A., Steiner H., Romig H., Keck S., Baader M., Grim M.G., Baumeister R., and Haass C. Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch. Nat. Cell Biol. 2 (2000) 205-211
28. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
29. Kowalska A. Genetic basis of neurodegeneration in familial Alzheimer's disease. Pol. J. Pharmacol. 56 (2004) 171-178
30. Cruts, M.a.R., R., Vol. 2006 August 2006.
31. Selkoe D.J. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J. Clin. Invest. 110 (2002) 1375-1381
32. Golde T.E. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 15 (2005) 84-87
33. Theuns J., Marjaux E., Vandenbulcke M., Van Laere K., Kumar-Singh S., Bormans G., Brouwers N., Van den Broeck M., Vennekens K., Corsmit E., Cruts M., De Strooper B., Van Broeckhoven C., and Vandenberghe R. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum. Mutat. 27 (2006) 888-896
34. Walker E.S., Martinez M., Brunkan A.L., and Goate A. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J. Neurochem. 92 (2005) 294-301
35. Chen Q., and Schubert D. Presenilin-interacting proteins. Expert Rev. Mol. Med. 2002 (2002) 1-18
36. Haass C., Lemere C.A., Capell A., Citron M., Seubert P., Schenk D., Lannfelt L., and Selkoe D.J. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat. Med. 1 (1995) 1291-1296
37. Walsh D.M., Hartley D.M., Condron M.M., Selkoe D.J., and Teplow D.B. In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-(Gly) Alzheimer's disease. Biochem. J. 355 (2001) 869-877
38. Kirkitadze M.D., Condron M.M., and Teplow D.B. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J. Mol. Biol. 312 (2001) 1103-1119
39. Chong Z.Z., Li F., and Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res. Brain Res. Rev. 49 (2005) 1-21
40. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., and Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70 (1998) 2212-2215
41. Stefani M., and Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81 (2003) 678-699
42. Sjogren M., and Blennow K. The link between cholesterol and Alzheimer's disease. World J. Biol. Psychiatry 6 (2005) 85-97
43. Cacabelos R., Fernandez-Novoa L., Lombardi V., Corzo L., Pichel V., and Kubota Y. Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications. Neurol. Res. 25 (2003) 567-580
44. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn M.A., Van Broeckhoven C., and Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 349 (1997) 151-154
45. Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., and Breteler M.M. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39 (1996) 1392-1397
46. Balakrishnan K., Verdile G., Mehta P.D., Beilby J., Nolan D., Galvao D.A., Newton R., Gandy S.E., and Martins R.N. Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J. Alzheimers Dis. 8 (2005) 269-282
47. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28 (2005) 202-208
48. Dwork A.J., Schon E.A., and Herbert J. Nonidentical distribution of transferrin and ferric iron in human brain. Neuroscience 27 (1988) 333-345
49. Frederickson C.J. Neurobiology of zinc and zinc-containing neurons. Int. Rev. Neurobiol. 31 (1989) 145-238
50. Droste T.E., and Smith R.M. Neurobiology of Trace Elements vol. 1 (1983), Humana Press, Clifton, NJ
51. Sensi S.L., Yin H.Z., Carriedo S.G., Rao S.S., and Weiss J.H. Preferential Zn2+influx through Ca2+-permeable AMPA/kainate channels triggers prolonged mitochondrial superoxide production. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 2414-2419
52. Cornett C.R., Markesbery W.R., and Ehmann W.D. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19 (1998) 339-345
53. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
54. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (1995) 973-977
55. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T., et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995) 775-778
56. Chyung J.H., Raper D.M., and Selkoe D.J. gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J. Biol. Chem. 280 (2005) 4383-4392
57. De Strooper B., Beullens M., Contreras B., Levesque L., Craessaerts K., Cordell B., Moechars D., Bollen M., Fraser P., George-Hyslop P.S., and Van Leuven F. Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. J. Biol. Chem. 272 (1997) 3590-3598
58. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., and Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4 (1998) 97-100
59. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George Hyslop P., and Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3 (1997) 67-72
60. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 (1996) 864-870
61. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., and Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391 (1998) 387-390
62. Herreman A., Hartmann D., Annaert W., Saftig P., Craessaerts K., Serneels L., Umans L., Schrijvers V., Checler F., Vanderstichele H., Baekelandt V., Dressel R., Cupers P., Huylebroeck D., Zwijsen A., Van Leuven F., and De Strooper B. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11872-11877
63. Feng R., Wang H., Wang J., Shrom D., Zeng X., and Tsien J.Z. Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8162-8167
64. Smith M.J., Sharples R.A., Evin G., McLean C.A., Dean B., Pavey G., Fantino E., Cotton R.G., Imaizumi K., Masters C.L., Cappai R., and Culvenor J.G. Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. Brain Res. Mol. Brain Res. 127 (2004) 128-135
65. Brunkan A.L., and Goate A.M. Presenilin function and gamma-secretase activity. J. Neurochem. 93 (2005) 769-792
66. Vetrivel K.S., Zhang Y.W., Xu H., and Thinakaran G. Pathological and physiological functions of presenilins. Mol. Neurodegener. 1 (2006) 4
67. Tu H., Nelson O., Bezprozvanny A., Wang Z., Lee S.F., Hao Y.H., Serneels L., De Strooper B., Yu G., and Bezprozvanny I. Presenilins form ER Ca2+leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 126 (2006) 981-993
68. Vito P., Lacana E., and D'Adamio L. Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science 271 (1996) 521-525
69. Alberici A., Moratto D., Benussi L., Gasparini L., Ghidoni R., Gatta L.B., Finazzi D., Frisoni G.B., Trabucchi M., Growdon J.H., Nitsch R.M., and Binetti G. Presenilin 1 protein directly interacts with Bcl-2. J. Biol. Chem. 274 (1999) 30764-30769
70. Passer B.J., Pellegrini L., Vito P., Ganjei J.K., and D'Adamio L. Interaction of Alzheimer's presenilin-1 and presenilin-2 with Bcl-X(L). A potential role in modulating the threshold of cell death. J. Biol. Chem. 274 (1999) 24007-24013
71. Li X., and Greenwald I. Additional evidence for an eight-transmembrane-domain topology for Caenorhabditis elegans and human presenilins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7109-7114
72. Dewji N.N., and Singer S.J. The seven-transmembrane spanning topography of the Alzheimer disease-related presenilin proteins in the plasma membranes of cultured cells. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 14025-14030
73. Lehmann S., Chiesa R., and Harris D.A. Evidence for a six-transmembrane domain structure of presenilin 1. J. Biol. Chem. 272 (1997) 12047-12051
74. Spasic D., Tolia A., Dillen K., Baert V., De Strooper B., Vrijens S., and Annaert W. Presenilin-1 maintains a nine transmembrane topology throughout the secretory pathway. J. Biol. Chem. (2006)
75. Laudon H., Hansson E.M., Melen K., Bergman A., Farmery M.R., Winblad B., Lendahl U., von Heijne G., and Naslund J. A nine-transmembrane domain topology for presenilin 1. J. Biol. Chem. 280 (2005) 35352-35360
76. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., and Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398 (1999) 513-517
77. Kimberly W.T., Xia W., Rahmati T., Wolfe M.S., and Selkoe D.J. The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J. Biol. Chem. 275 (2000) 3173-3178
78. Podlisny M.B., Citron M., Amarante P., Sherrington R., Xia W., Zhang J., Diehl T., Levesque G., Fraser P., Haass C., Koo E.H., Seubert P., St George-Hyslop P., Teplow D.B., and Selkoe D.J. Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue. Neurobiol. Dis. 3 (1997) 325-337
79. Thinakaran G., Borchelt D.R., Lee M.K., Slunt H.H., Spitzer L., Kim G., Ratovitsky T., Davenport F., Nordstedt C., Seeger M., Hardy J., Levey A.I., Gandy S.E., Jenkins N.A., Copeland N.G., Price D.L., and Sisodia S.S. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17 (1996) 181-190
80. Ratovitski T., Slunt H.H., Thinakaran G., Price D.L., Sisodia S.S., and Borchelt D.R. Endoproteolytic processing and stabilization of wild-type and mutant presenilin. J. Biol. Chem. 272 (1997) 24536-24541
81. Steiner H., Capell A., Pesold B., Citron M., Kloetzel P.M., Selkoe D.J., Romig H., Mendla K., and Haass C. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. 273 (1998) 32322-32331
82. Capell A., Grunberg J., Pesold B., Diehlmann A., Citron M., Nixon R., Beyreuther K., Selkoe D.J., and Haass C. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J. Biol. Chem. 273 (1998) 3205-3211
83. Hebert S.S., Godin C., and Levesque G. Oligomerization of human presenilin-1 fragments. FEBS Lett. 550 (2003) 30-34
84. Haass C., and Steiner H. Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol. 12 (2002) 556-562
85. Cervantes S., Gonzalez-Duarte R., and Marfany G. Homodimerization of presenilin N-terminal fragments is affected by mutations linked to Alzheimer's disease. FEBS Lett. 505 (2001) 81-86
86. Brown M.S., Ye J., Rawson R.B., and Goldstein J.L. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100 (2000) 391-398
87. Kimberly W.T., LaVoie M.J., Ostaszewski B.L., Ye W., Wolfe M.S., and Selkoe D.J. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6382-6387
88. Kimberly W.T., Esler W.P., Ye W., Ostaszewski B.L., Gao J., Diehl T., Selkoe D.J., and Wolfe M.S. Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s). Biochemistry 42 (2003) 137-144
89. Takasugi N., Tomita T., Hayashi I., Tsuruoka M., Niimura M., Takahashi Y., Thinakaran G., and Iwatsubo T. The role of presenilin cofactors in the gamma-secretase complex. Nature 422 (2003) 438-441
90. Hu Y., Ye Y., and Fortini M.E. Nicastrin is required for gamma-secretase cleavage of the Drosophila Notch receptor. Dev. Cell 2 (2002) 69-78
91. Yu G., Nishimura M., Arawaka S., Levitan D., Zhang L., Tandon A., Song Y.Q., Rogaeva E., Chen F., Kawarai T., Supala A., Levesque L., Yu H., Yang D.S., Holmes E., Milman P., Liang Y., Zhang D.M., Xu D.H., Sato C., Rogaev E., Smith M., Janus C., Zhang Y., Aebersold R., Farrer L.S., Sorbi S., Bruni A., Fraser P., and St George-Hyslop P. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 407 (2000) 48-54
92. Li T., Ma G., Cai H., Price D.L., and Wong P.C. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. J. Neurosci. 23 (2003) 3272-3277
93. Zhang Y.W., Luo W.J., Wang H., Lin P., Vetrivel K.S., Liao F., Li F., Wong P.C., Farquhar M.G., Thinakaran G., and Xu H. Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components. J. Biol. Chem. 280 (2005) 17020-17026
94. Chen F., Hasegawa H., Schmitt-Ulms G., Kawarai T., Bohm C., Katayama T., Gu Y., Sanjo N., Glista M., Rogaeva E., Wakutani Y., Pardossi-Piquard R., Ruan X., Tandon A., Checler F., Marambaud P., Hansen K., Westaway D., St George-Hyslop P., and Fraser P. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440 (2006) 1208-1212
95. Steiner H., Kostka M., Romig H., Basset G., Pesold B., Hardy J., Capell A., Meyn L., Grim M.L., Baumeister R., Fechteler K., and Haass C. Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat. Cell Biol. 2 (2000) 848-851
96. Schroeter E.H., Kisslinger J.A., and Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393 (1998) 382-386
97. Struhl G., and Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398 (1999) 522-525
98. Levitan D., Doyle T.G., Brousseau D., Lee M.K., Thinakaran G., Slunt H.H., Sisodia S.S., and Greenwald I. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14940-14944
99. Koo E.H., and Kopan R. Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat. Med. 10 Suppl (2004) S26-S33
100. Fraser P.E., Yang D.S., Yu G., Levesque L., Nishimura M., Arawaka S., Serpell L.C., Rogaeva E., and St George-Hyslop P. Presenilin structure, function and role in Alzheimer disease. Biochim. Biophys. Acta 1502 (2000) 1-15
101. Sato N., Hori O., Yamaguchi A., Lambert J.C., Chartier-Harlin M.C., Robinson P.A., Delacourte A., Schmidt A.M., Furuyama T., Imaizumi K., Tohyama M., and Takagi T. A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue. J. Neurochem. 72 (1999) 2498-2505
102. Higashide S., Morikawa K., Okumura M., Kondo S., Ogata M., Murakami T., Yamashita A., Kanemoto S., Manabe T., and Imaizumi K. Identification of regulatory cis-acting elements for alternative splicing of presenilin 2 exon 5 under hypoxic stress conditions. J. Neurochem. 91 (2004) 1191-1198
103. Matsuzaki S., Manabe T., Katayama T., Nishikawa A., Yanagita T., Okuda H., Yasuda Y., Miyata S., Meshitsuka S., and Tohyama M. Metals accelerate production of the aberrant splicing isoform of the presenilin-2. J. Neurochem. 88 (2004) 1345-1351
104. Kwok J.B., Halliday G.M., Brooks W.S., Dolios G., Laudon H., Murayama O., Hallupp M., Badenhop R.F., Vickers J., Wang R., Naslund J., Takashima A., Gandy S.E., and Schofield P.R. Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J. Biol. Chem. 278 (2003) 6748-6754
105. Crook R., Verkkoniemi A., Perez-Tur J., Mehta N., Baker M., Houlden H., Farrer M., Hutton M., Lincoln S., Hardy J., Gwinn K., Somer M., Paetau A., Kalimo H., Ylikoski R., Poyhonen M., Kucera S., and Haltia M. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat. Med. 4 (1998) 452-455
106. Evin G., Smith M.J., Tziotis A., McLean C., Canterford L., Sharples R.A., Cappai R., Weidemann A., Beyreuther K., Cotton R.G., Masters C.L., and Culvenor J.G. Alternative transcripts of presenilin-1 associated with frontotemporal dementia. NeuroReport 13 (2002) 917-921
107. Dermaut B., Kumar-Singh S., Engelborghs S., Theuns J., Rademakers R., Saerens J., Pickut B.A., Peeters K., van den Broeck M., Vennekens K., Claes S., Cruts M., Cras P., Martin J.J., Van Broeckhoven C., and De Deyn P.P. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann. Neurol. 55 (2004) 617-626
108. F. Assal, R. Sztajzel, A. Carota, J.M. Annoni, J. Bogousslavsky. Neurodegeneration and cerebrovascular disease: causal or incidental link? Rev. Med. Suisse 2 (2006) 1180-82, 1184.
109. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerriere A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., and Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38 (2006) 24-26
110. Joutel A., Vahedi K., Corpechot C., Troesch A., Chabriat H., Vayssiere C., Cruaud C., Maciazek J., Weissenbach J., Bousser M.G., Bach J.F., and Tournier-Lasserve E. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 350 (1997) 1511-1515
111. Vikelis M., Xifaras M., and Mitsikostas D.D. CADASIL: a short review of the literature and a description of the first family from Greece. Funct. Neurol. 21 (2006) 77-82
112. Meredith Jr. J.E., Wang Q., Mitchell T.J., Olson R.E., Zaczek R., Stern A.M., and Seiffert D. Gamma-secretase activity is not involved in presenilin-mediated regulation of beta-catenin. Biochem. Biophys. Res. Commun. 299 (2002) 744-750
113. De Strooper B., and Annaert W. Where Notch and Wnt signaling meet. The presenilin hub. J. Cell Biol. 152 (2001) F17-F20
114. Noll E., Medina M., Hartley D., Zhou J., Perrimon N., and Kosik K.S. Presenilin affects arm/beta-catenin localization and function in Drosophila. Dev. Biol. 227 (2000) 450-464
115. Soriano S., Kang D.E., Fu M., Pestell R., Chevallier N., Zheng H., and Koo E.H. Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J. Cell Biol. 152 (2001) 785-794
116. Murayama M., Tanaka S., Palacino J., Murayama O., Honda T., Sun X., Yasutake K., Nihonmatsu N., Wolozin B., and Takashima A. Direct association of presenilin-1 with beta-catenin. FEBS Lett. 433 (1998) 73-77
117. Zhang Z., Hartmann H., Do V.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Sommer B., van de Wetering M., Clevers H., Saftig P., De Strooper B., He X., and Yankner B.A. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395 (1998) 698-702
118. Kang D.E., Soriano S., Frosch M.P., Collins T., Naruse S., Sisodia S.S., Leibowitz G., Levine F., and Koo E.H. Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway. J. Neurosci. 19 (1999) 4229-4237
119. Wagner U., Brownlees J., Irving N.G., Lucas F.R., Salinas P.C., and Miller C.C. Overexpression of the mouse dishevelled-1 protein inhibits GSK-3beta-mediated phosphorylation of tau in transfected mammalian cells. FEBS Lett. 411 (1997) 369-372
120. Leimer U., Lun K., Romig H., Walter J., Grunberg J., Brand M., and Haass C. Zebrafish (Danio rerio) presenilin promotes aberrant amyloid beta-peptide production and requires a critical aspartate residue for its function in amyloidogenesis. Biochemistry 38 (1999) 13602-13609
121. Groth C., Nornes S., McCarty R., Tamme R., and Lardelli M. Identification of a second presenilin gene in zebrafish with similarity to the human Alzheimer's disease gene presenilin2. Dev. Genes Evol. 212 (2002) 486-490
122. Nornes S., Groth C., Camp E., Ey P., and Lardelli M. Developmental control of Presenilin1 expression, endoproteolysis, and interaction in zebrafish embryos. Exp. Cell Res. 289 (2003) 124-132
123. Crowther D.C., Kinghorn K.J., Miranda E., Page R., Curry J.A., Duthie F.A., Gubb D.C., and Lomas D.A. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 132 (2005) 123-135
124. Finelli A., Kelkar A., Song H.J., Yang H., and Konsolaki M. A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol. Cell Neurosci. 26 (2004) 365-375
125. Li X., and Greenwald I. HOP-1, a Caenorhabditis elegans presenilin, appears to be functionally redundant with SEL-12 presenilin and to facilitate LIN-12 and GLP-1 signaling. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12204-12209
126. Arduengo P.M., Appleberry O.K., Chuang P., and L'Hernault S.W. The presenilin protein family member SPE-4 localizes to an ER/Golgi derived organelle and is required for proper cytoplasmic partitioning during Caenorhabditis elegans spermatogenesis. J. Cell Sci. 111 Pt 24 (1998) 3645-3654
127. L'Hernault S.W., and Arduengo P.M. Mutation of a putative sperm membrane protein in Caenorhabditis elegans prevents sperm differentiation but not its associated meiotic divisions. J. Cell Biol. 119 (1992) 55-68
128. Link C.D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9368-9372
129. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., and LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24 (2003) 1063-1070
130. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and Laferla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
131. Ashe K.H. Mechanisms of memory loss in Abeta and tau mouse models. Biochem. Soc. Trans. 33 (2005) 591-594
132. Tatebayashi Y., Miyasaka T., Chui D.H., Akagi T., Mishima K., Iwasaki K., Fujiwara M., Tanemura K., Murayama M., Ishiguro K., Planel E., Sato S., Hashikawa T., and Takashima A. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13896-13901
133. Tomasiewicz H.G., Flaherty D.B., Soria J.P., and Wood J.G. Transgenic zebrafish model of neurodegeneration. J. Neurosci. Res. 70 (2002) 734-745
134. Scheer N., and Campos-Ortega J.A. Use of the Gal4-UAS technique for targeted gene expression in the zebrafish. Mech. Dev. 80 (1999) 153-158
135. Steiner H., Winkler E., Edbauer D., Prokop S., Basset G., Yamasaki A., Kostka M., and Haass C. PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin. J. Biol. Chem. 277 (2002) 39062-39065
136. Campbell W.A., Yang H., Zetterberg H., Baulac S., Sears J.A., Liu T., Wong S.T., Zhong T.P., and Xia W. Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss. J. Neurochem. 96 (2006) 1423-1440
137. Dovey H.F., John V., Anderson J.P., Chen L.Z., de Saint P., de Saint Andrieu L.Y., Fang S.B., Freedman B., Folmer E., Goldbach E.J., Holsztynska K.L., Hu K.L., Johnson-Wood S.L., Kennedy D., Kholodenko J.E., Knops L.H., Latimer M., Lee Z., Liao I.M., Lieberburg R.N., Motter L.C., Mutter J., Nietz K.P., Quinn K.L., Sacchi P.A., Seubert G.M., Shopp E.D., Thorsett J.S., Tung J., Wu S., Yang C.T., Yin D.B., Schenk P.C., May L.D., Altstiel M.H., Bender L.N., Boggs T.C., Britton J.C., Clemens D.L., Czilli D.K., Dieckman-McGinty J.J., Droste K.S., Fuson B.D., Gitter P.A., Hyslop E.M., Johnstone W.Y., Li S.P., Little T.E., Mabry F.D., and Miller J.E. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76 (2001) 173-181
138. Geling A., Steiner H., Willem M., Bally-Cuif L., and Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep. 3 (2002) 688-694
139. Donoviel D.B., Hadjantonakis A.K., Ikeda M., Zheng H., Hyslop P.S., and Bernstein A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev. 13 (1999) 2801-2810
140. Thinakaran G., Harris C.L., Ratovitski T., Davenport F., Slunt H.H., Price D.L., Borchelt D.R., and Sisodia S.S. Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J. Biol. Chem. 272 (1997) 28415-28422
141. Nornes, S.a.L., M. Manuscript in progress.
142. Musa A., Lehrach H., and Russo V.A. Distinct expression patterns of two zebrafish homologues of the human APP gene during embryonic development. Dev. Genes Evol. 211 (2001) 563-567
143. Sarasa M., Sorribas V., Terradoa J., Climent S., Palacios J.M., and Mengod G. Alzheimer beta-amyloid precursor proteins display specific patterns of expression during embryogenesis. Mech. Dev. 94 (2000) 233-236
144. Carvan III M.J., Sonntag D.M., Cmar C.B., Cook R.S., Curran M.A., and Miller G.L. Oxidative stress in zebrafish cells: potential utility of transgenic zebrafish as a deployable sentinel for site hazard ranking. Sci. Total Environ. 274 (2001) 183-196